BeiGene Ltd.
(NASDAQ : BGNE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.84%348.830.0%$6190.05m
NVAXNovavax, Inc. -3.17%203.2479.8%$835.18m
BNTXBioNTech SE 0.35%281.960.0%$757.04m
SNSSSunesis Pharmaceuticals, Inc. -4.84%10.610.7%$741.68m
NTLAIntellia Therapeutics, Inc. -6.88%137.712.3%$596.78m
AMGNAmgen, Inc. 1.22%247.721.3%$537.34m
BIIBBiogen, Inc. -0.29%325.401.7%$533.59m
VRTXVertex Pharmaceuticals, Inc. 2.29%200.501.9%$461.09m
REGNRegeneron Pharmaceuticals, Inc. -0.09%586.352.7%$443.78m
GILDGilead Sciences, Inc. 0.54%69.021.0%$385.04m
ILMNIllumina, Inc. 1.85%495.513.5%$273.43m
CRSPCRISPR Therapeutics AG -2.00%122.270.6%$201.32m
OCGNOcugen, Inc. -1.98%6.940.0%$158.32m
ALNYAlnylam Pharmaceuticals, Inc. 0.33%182.418.3%$129.23m
EXASEXACT Sciences Corp. -0.07%117.9518.1%$126.26m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.